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The extracellular ligand, Wnt, and its receptors are involved in signal transduction and play 
an important role in axis formation and neural development. In neurodegenerative disorders 
such as Alzheimer’s disease (AD), a decrease of the intracellular Wnt effector, β-catenin, has 
been linked to amyloid-β-peptide-induced neurotoxicity. Despite this knowledge, targeting 
Wnt inhibitors as potential biomarkers has not been explored, and harnessing Wnt activators 
as therapeutic candidates remains largely not investigated. A wide acting family of Wnt 
mediators, secreted frizzled-related proteins (sFRPs), has not been probed so far as molecular 
indicators of disease occurrence and progression of Alzheimer’s. Unlike the effect of the 
Dickkopf (DKK) family of Wnt antagonists on AD, the sFRP molecules have a more 
pleiotropic impact on the Wnt signaling cascade and probably have a far-reaching 
involvement in neurodegeneration. The role of sFRPs has been poorly described in AD, and 
in this review, we analyze the present status of the role of sFRPs on neurodegeneration, their 
likely involvement, and potential implications in treatment modalities of AD. This 
information would provide valuable clues for the development of potential therapeutic targets 
for aberrant neurodegenerative disorders.  
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Neurodegenerative diseases represent a diverse spectrum of neuronal disorders with 
progressive dysfunctions in the nervous system. Pathologically, they are identified by the 
presence of disease-specific protein aggregations and misfoldings in specific regions of the 
brain (Jucker & Walker, 2013). Although several neurological disorders have been identified, 
attention has been given to only a handful, including Alzheimer’s disease (AD), Parkinson’s 
disease (PD), Huntington’s disease, and amyotrophic lateral sclerosis (Ross & Poirier, 2004). 
The prevalence and incidence of these diseases increase with age (Melo et al., 2011), and 
reaches a peak well before the maximum lifespan. For instance, AD is the 5th leading cause 
of death globally for those aged 65 and older. An increase in incidence of 40% of AD has 
been reported worldwide and is predicted to rise dramatically to one new case diagnosed 
every 33 seconds, which is projected to lead to around one million new cases per year by 
2050 (http://www.alz.org/facts/). 
Clinically, AD is characterized by the gradual decline of neuro-cognitive functions (Gouras et 
al., 2010). The hallmark identification of β-amyloid (Aβ) deposits and neuro-fibrillary tangles 
(NFTs), formed by hyperphosphorylated tau protein in the sub-cortical regions of the brain 
(as reported in several studies Armstrong, 2011; Ittner and Götz, 2011; Blennow et al., 
2006)), correlates with the synaptic dysfunctions and massive neuronal death observed in AD 
(Fuentealba et al., 2004).  The Aβ deposition also results in the activation of pro-
inflammatory cytokines primarily in the glial cells (Lindberg et al., 2005), initiation of the 
complement cascade (Aisen, 1997), and the induction of pro-inflammatory enzymes such as 
inducible nitric oxide synthase and cyclooxygenase-2; these factors further contribute 
to neuronal dysfunction and cell death (Brown and Bal-Price, 2003). The key focus of 
current AD research is on the underlying disease mechanisms, and a number of studies have 
4 
 
been conducted globally to identify the potential biomarkers for this disease.  
 
Wnt signaling in AD 
Although the underlying molecular map of AD remains elusive, impaired Wnt signaling 
events are well known to promote AD pathogenesis (Inestrosa and Toledo, 2008).  Wnts 
(Wingless) are a family of 19 members of secreted lipoglycoproteins that are multifunctional 
in nature (Willert and Nusse, 2012) . The Wnt pathways are crucial in cell fate determination 
during animal development (Martin and Kimelman, 2012) and are known to regulate many 
developmental events in the nervous system, including the maintenance of synapses during 
brain development (van Amerongen and Nusse, 2009; Inestrosa and Varela- Nallar, 2014) 
and also in dorsal-ventral patterning in the forebrain (Harrison-Uy and Pleasure, 2012; 
Quinlan et al., 2009). Furthermore, ablation of Wnt variants in neuro-degenerative diseases 
has been reported to result in severe midbrain damage and hippocampus dysfunction (Arenas, 
2014; Varela-Nallar and Inestrosa, 2013). Different mechanisms of Wnt signaling have been 
identified; namely, the ß-catenin dependent and ß-catenin independent pathways. The Wnt/ß-
catenin pathway has been most extensively studied in neurodegeneration, especially during 
AD progression (Wan et al., 2014; Godoy et al., 2014). In this pathway, in the presence of 
Wnt ligands, signals are transduced to the nucleus via ß-catenin through the interaction of 
Wnt with a 7-transmembrane receptor complex, the frizzled receptor (FZD), and a co-
receptor corresponding to the low density lipoprotein receptor-related protein 5/6 (LRP 5/6) 
membrane protein, which leads to the activation of dishevelled (DVL) (MacDonald and He, 
2012; Esteve et al., 2011).  
 These events stabilize intracellular ß-catenin through the axin complex, which is composed 
of axin, the tumor suppressor adenomatous polyposis coli gene product (APC), and glycogen 
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synthase kinase 3 beta (GSK3ß), thereby preventing its phosphorylation and ubiquitin 
mediated degradation (Fig 1). It has been reported that, in response to depolarization, the 
maintenance of intracellular ß-catenin levels is crucial in regulating neuronal homeostasis and 
synaptic modulations (Murase et al., 2002).  Depleted levels of ß-catenin have been 
correlated with synaptic loss and Aβ deposition (Chen and Bodles, 2007), and have been 
identified as key factors prior to the onset of neuronal death in many neurodegenerative 
diseases including AD. The ß-catenin-independent pathway of Wnt signaling has two arms: 
the Wnt/planar cell polarity (PCP) pathway and the Wnt/Ca2+ signaling pathway. In the 
Wnt/Ca2+ pathway, Wnts binds to FZD resulting in stimulation of heterotrimeric G proteins, 
which further activates phospholipase C. This leads to increased Ca2+ release and activates 
two kinases: Ca2+-calmodulin dependent protein kinase-II and protein kinase-C. This, in turn, 
stimulates transcription factors such as cAMP response element-binding protein-1. In the 
PCP pathway, Wnt proteins bind to FZD, which activates small GTP-binding proteins Rho 
and Rac and jun N-terminal kinase via DVL. This interaction results in cytoskeletal 
regulation and involves polarized cell shape changes and migration (Fig 1). 
Wnt/ß-catenin signaling plays a crucial role in embryonic development of most tissues and 
organs of the body (van Amerongen and Nusse, 2009), and it is also important in the adult 
organisms, where it maintains hair, skin (Alonso and Fuchs, 2003), intestinal health, and 
hematopoiesis (Malhotra and Kincade, 2009). Aberrant regulation of ß-catenin levels and the 
ß-catenin signaling pathway have been associated with the onset of fibrosis and metabolic 
disease, as well as many cancers including lung, pancreas, breast, and colorectal cancers 
(Paul and Dey, 2008; Kahn, 2014). The Wnt/ß-catenin dependent pathway has also been 
extensively studied in neurodegenerative diseases, especially with respect to its involvement 
in AD progression. For example, studies on ß-catenin in neuronal cells have reported that 
neural depolarization induces ß-catenin redistribution from dendritic shafts into spines, where 
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it interacts with cadherin to influence synaptic size and strength (Murase et al., 2002); thus, 
the maintenance of intracellular ß-catenin levels is crucial in the regulation of neuronal 
homeostasis and synaptic modulations. It has also been shown that depletion of ß-catenin 
levels correlates with synaptic loss and Aβ deposition (Inestrosa and Arenas, 
2010).Furthermore, a deficiency in LRP6-mediated Wnt signaling in an AD transgenic mouse 
model led to greater amyloid deposition due to greater Aβ production; and deletion of the 
LRP6 gene in mice forebrain neurons led to age-dependent deficits in synapse integrity as 
well as memory deficits (Liu et al., 2014).  
Many studies have investigated the relationship between components of the Wnt/ß-catenin 
signaling pathway and AD-related proteins. For example, the amyloid precursor protein 
(APP) intracellular domain (AICD), which is present in higher levels in AD, has been shown 
to bind to GSK3β, activating it and thereby reducing β-catenin levels. Another very pertinent 
observation showing a direct link between amyloid-β and Wnt signaling indicated that 
amyloid-β binds to the FZD cysteine-rich domain in close proximity to the Wnt-binding site 
and inhibits the Wnt β-catenin signaling pathway (Magdesian et al., 2008).  In AICD-
transgenic mice (Ryan and Pimplikar, 2005), studies found hyper-phosphorylation and 
aggregation of tau, neurodegeneration, and deficits in working memory that could be 
prevented by treatment with lithium chloride, a GSK3β inhibitor (Ghosal et al., 2009). 
However, the AICD-Wnt pathway relationship needs further study, as AICD has also been 
shown to bind to β-catenin (Zhou et al., 2011), and some neuronal studies have found GSK3β 
activation causes neurite retraction (Sanchez et al., 2001). AICD-stimulated GSK3β has 
resulted in neurite outgrowth in the PC12 and N2A neuronal cell lines as well as in primary 
neurons (Zhou et al., 2011). The AICD pathway also should be investigated further as it 
appears to be able to contribute to AD pathology independently of Aβ. Another controversial 
link between AICD and AD involves neprilysin (NEP), a major Aβ-degrading enzyme; 
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although some previous studies have not agreed with these findings, a recent comprehensive 
study has found NEP expression to be dependent on AICD levels in several transgenic AD 
mouse models as well as in cell culture models (Grimm et al., 2015). In recent years, GSK3β, 
being a key modulator of the Wnt β-catenin pathway, has emerged as one of the most 
relevant targets for AD treatment (Martinez and Perez, 2008). Lithium chloride (LiCl), a 
classic inhibitor of GSK3β, has been shown to prevent neurotoxicity by reducing amyloid-β 
production in a mouse model of AD (Phiel et al., 2003). LiCl has also been reported to inhibit 
amyloid-ß induced synaptic degeneration in elderly AD patients with bipolar disorders 
(Valvezan and Klein, 2012). An increasing number of novel GSK3β inhibitors, which are 
both ATP-competitive and non-ATP-competitive, have been developed; particularly 
promising are the non-ATP-competitive GSK3β inhibitors, since they are more selective and 
less toxic (King et al., 2014), examples of which being L803-mts (Plotkin et al., 2003; 
Kaidanovich-Beilin et al., 2004) and VP0.7 (Palomo et al., 2011). The typical ATP-
competitive GSK3 inhibitors include indirubin (Leclerc et al., 2001), paullone compounds 
(Leost et al., 2000), SB415286 and SB216763 (Coghlan et al., 2000), and AR-A014418 (Bhat 
et al., 2003). Similarly, it has been shown that bromoindirubin-30-oxime (6-BIO), another 
GSK3ß inhibitor, was able to reduce amyloid-ß formation and prevent neuronal apoptosis 
(Silva-Alvarez et al., 2013).  
Wnt signaling has also been shown to influence levels of β-amyloid precursor protein 
cleaving enzyme-1 (BACE1), as chromatin analysis has demonstrated that β-catenin binds 
specifically to regions within the BACE1 promoter that contain putative T-cell 
factor/lymphoid enhancer factor (TCF/LEF) motifs, consistent with canonical Wnt target 
regulation (Parr et al., 2015). Furthermore, TCF4 was found to act as a transcriptional 
repressor of BACE1. All these results support the concept that the modulation of Wnt/β-
catenin signaling may be a pathway to potential preventative treatments for AD.  
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Studies of Wnt signaling and mitochondria have found that β-catenin dependent Wnt 
signaling (via the Wnt3a ligand) prevents the permeabilization of mitochondrial membranes, 
induced by Aβ oligomers, through the inhibition of the mitochondrial permeability transition 
pore. It has also been found that β-catenin independent Wnt signaling, through the Wnt5a 
ligand, protects mitochondria from mitochondrial fission-fusion alterations that occur in AD, 
and also modulates B-cell lymphoma 2 (Bcl2) increases, which are induced by Aβ oligomers 
(Arrázola et al., 2015; Silva-Alvarez et al., 2013). These findings suggest that modulation of 
Wnt signaling (both β-catenin dependent and independent) could also protect against AD-
related mitochondrial dysfunction. Another emerging line of evidence links Wnt signaling 
with the inflammatory response in microglia, which is central to neuroinflammation in 
neurodegenerative diseases. Disease associated β-catenin accumulation was shown in 
microglia in vivo in mice with Alzheimer's-like pathology (Schnurrbusch et al., 1990).  The 
Wnts were also shown to differentially activate β-catenin dependent and independent 
signaling in a murine microglia cell line, and are possible regulators of microglia-mediated 
neuroinflammation (Kilander et al., 2011).  
 
Wnt antagonists as key modulators in AD cell signaling 
Antagonists of Wnt have been shown to work in tandem with Wnt activators during 
development to promote or inhibit a variety of developmental pathways. They are reported to 
act either intracellularly by affecting signal transduction, or extracellularly by altering their 
ability to bind the membrane-receptor complex (Cruciat and Niehrs, 2013). The inhibitors of 
Wnt are classically grouped into two functional classes: the Dickkopf (Dkk) group of Wnt 
antagonists comprised of the Dkk family 1-5, which regulate Wnt signaling by binding to the 
Frizzled co- receptor component LRP5/LRP6; and the secreted frizzled-related protein 
(sFRP) group, which binds directly either to Wnt or its receptor, FZD, and modulates the 
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downstream signals (Kawano and Kypta, 2003). The role of Dkk-1 in response to Wnt 
signaling, and its antagonistic properties, has been studied extensively by several groups. 
Higher expression of Dkk-1 has been associated with cell death and DNA damage (Slee et 
al., 2004), while the expression level of Dkk-1 has been shown to be low in the normal 
healthy adult brain (Galli et al., 2014; Scott and Brann, 2013). Early reports from studies of 
cultured cortical neurons describe a potential role of Dkk-1 in the induction of Aß toxicity-
mediated inhibition of Wnt cascades through interaction with LRP5/6 (Caraci et al., 2008; 
Caricasole et al., 2004). In parallel, significantly increased expression of Dkk-1 has also been 
detected in post-mortem AD brains and transgenic mouse AD models (Lieven et al., 2010; 
Mukhopadhyay et al., 2001); in fact, in one AD mouse model, Dkk-1 has been found to 
colocalize with hyper-phosphorylated tau-bearing neurons and active GSK3β (Rosi et al., 
2010).  
 Furthermore, in studies of cultured neuronal cells that had high levels of Dkk-1 due to 
incubation with Aβ peptides, it was found that antisense knockdown of Dkk-1 resulted in 
significant inhibition of the Aβ-induced hyper-phosphorylation of tau protein (Caricasole et 
al., 2004). Recent studies of SAMP8 (senescence-accelerated) mice detected higher than 
normal levels of Dkk-1, activated GSK3β, and hyper-phosphorylated tau, along with higher 
than normal levels of β-catenin that had been phosphorylated and ready for degradation; and 
lower protein levels of the anti-apoptotic protein Bcl2, a Wnt target gene (Itasaki et al., 
2003). Together, all these data suggest that Dkk-1 plays a central role in the pathological 
cascades of AD. 
In the ß-catenin Wnt pathway, accumulation of ß-catenin has been shown to be inhibited by 
the active binding of Wise/SOST (Sclerostin) antagonist family members through their 
interaction with either Wnt-1 or Wnt-3a in Xenopus animal cap cells (Bayod et al., 2015). A 
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similar observation was reported with other Wnt antagonists such as Wnt inhibitory factor 
(WIF)-1, which is expressed in the nervous system (Bayod et al., 2015) where it mediates ß-
catenin degradation by direct interaction with Wnt ligands. Although there are reports on the 
Wnt inhibitors acting through the LRP pathway, little is known about the inhibitors acting 
through the Frizzled receptor, namely the sFRPs, and their role as Wnt inhibitors in 
neurodegenerative diseases. Here, we review the recent developments in sFRP-Wnt 
interactions and the emerging role of sFRPs as key Wnt antagonists in AD neuropathology. 
sFRPs as multifunctional regulators 
sFRPs are known to bind directly to Wnt, and have sequence and structural similarities with 
FZD proteins (Rattner et al., 1997; Finch et al., 1997). The sFRP family is comprised of 5 
members in which sFRP1, 2, and 5 are clustered together as a group based on their sequence 
similarities, and are distantly related to the other cluster comprising sFRP3 and sFRP4 
(Garcia-Hoyos et al., 2004). Initial studies on sFRPs in Xenopus embryos (Leyns et al., 1997) 
designated them as Wnt antagonists by their ability to bind to Wnt and block Wnt/ß-catenin 
signaling. The role of sFRP was further demonstrated in Drosophila (Lin and Perrimon, 1999; 
Uren et al., 2000) by their ability to inhibit the activity of wingless-ligand Wg, a homologue 
of Wnt. Since this discovery, the functions of sFRPs have been progressively unravelled to 
demonstrate that they have multifunctional roles in regulating Wnt signaling in development 
and disease (Surana et al., 2014). The binding affinity of sFRPs has been shown to vary 
between their Wnt partners (Galli et al., 2014). and the sFRPs are reported to initiate complex 
formation with FZD proteins (Kawano and Kypta, 2003; Misra and Matise, 2010), indicating 
that the molecule could interact not only with Wnt but also with FZD receptors. sFRPs have 
two independent domains: the N-terminus consisting of a secretory signal peptide and a 
cysteine-rich domain (CRD), which is identical to the putative Wnt binding site of FZD 
receptors; and the C-terminus end, which has heparin binding residues and a netrin-related 
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motif (NTR) (Dann et al., 2001). The overall functions of the NTR are not defined, yet there 
are studies reporting its involvement in Wnt binding (Lopez- Rios et al., 2008) and in 
antagonizing tube formation and promoting apoptosis of human umbilical vein endothelial 
cells (Longman et al., 2012). Despite the conflicting reports on these two domains in 
potentiating Wnt activities (Dann et al., 2001; Bovolenta et al., 2008), a parallel study by 
Bhat et al, has demonstrated the fundamental importance of both domains in modulating Wnt 
dependent and independent signaling cascades (Bhat et al., 2007). However, due to the 
sequence resemblance of the CRD with FZD proteins, the CRDs of sFRPs are more recently 
postulated to be crucial for inhibiting Wnt binding to FZD (Scott and Brann, 2013; Martin-
Manso et al., 2011). The ability of sFRPs to bind FZD via their CRD by forming homo- and 
heterodimers can also stimulate signal transduction (Carron et al., 2003).  The biphasic effect 
of sFRPs, mainly via their CRD region, is dependent on their concentration and the cellular 
context. sFRP1 and 2 have been shown to either increase or decrease β-catenin 
stabilization depending on the cell type and the expression pattern of the FZD receptors 
(Xavier et al., 2014). The extracellular stoichiometry of sFRPs, Wnt, and FZD, and the 
intricate interplay of these molecules with each other is probably a deciding factor in 
determining whether the balance swings to sFRPs being potentiators or inhibitors of Wnt 
signaling. 
 
sFRPs can function as signal coordinators when multiple cascades are operating in order to 
determine cell fate and development. For instance, the role of sFRP1 in regulating neural cell 
proliferation during development has been demonstrated by Augustine and co-workers 
(Augustine et al., 2001), where they detected a strong expression of sFRP-1 in the developing 
neocortex of the mouse during the entire period when neurons for the neocortex were being 
generated and allocated to their final resting positions. sFRP1 has been implicated in 
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angiogenesis (Dufourcq et al., 2002), retinal cell differentiation (Kiefer et al., 2013 ) and 
axon guidance (Drescher, 2005; Rodriguez et al., 2005). A study by Rodriguez et al. [25] 
reported the possibility of inactivated sFRP1 and 2 being able to perturb retinal neurogenesis 
in the mouse embryo. A concentration dependent functional role of sFRP1 and 2 in 
promoting dopaminergic neuron differentiation has also been demonstrated (Kele et al., 
2012). Concurrently, a deletion study with sFRP3 alone reported its implication in the 
neurogenesis of adult hippocampal cells (Jang et al., 2013).  
The pro-apoptotic role of sFRP4 has been well established, initially by Dharmarajan and co-
workers, in reproductive tissues such as the mammary gland (Constantinou et al., 2008),  
ovary (Drake et al., 2003), corpus luteum (Guo et al., 1998) and the uterus (Hewitt et al., 
2006). However, the apoptotic function of sFRP4 has been rendered inactive in some cancers 
(He et al., 2005; Brebi et al., 2014). For example, in ovarian cancer, loss of sFRP4 expression 
results in an aggressive phenotype with poor prognosis (Jacob et al., 2012; Saran et al., 2012). 
The role of sFRP4 in glioblastoma and head and neck cancers has been recently reported 
from our group (Warrier et al., 2013; Warrier et al., 2014). We have shown that sFRP4 
clearly sensitizes the cancer stem cells to chemotherapeutics by inhibiting the Wnt/ß-catenin 
pathway and initiating the apoptotic cascade. Additionally, sFRP4 was seen to undergo 
hypermethylation at the promoter region in several glioma cell lines (Schiefer et al., 
2014).Furthermore, we have recently demonstrated the role of sFRP4 in inhibiting the 
stemness of glioma stem cells and inducing apoptosis (Bhuvanalakshmi et al., 2015). sFRP4 
also blocked other typical cancer stem cells traits such as epithelial to mesenchymal transition 
in glioma stem cells (Bhuvanalakshmi et al., 2015). These studies validate the hypothesis that 
the downregulation of sFRP4 facilitates cancer stem cell proliferation in brain tumors.  
Beyond their role as an inhibitor, sFRPs stabilize Wnts and regulate both Wnt and bone 
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morphogenetic protein (BMP) signals for maintaining neural tube functions in vertebrates 
(Misra and Matise, 2010; Stuckenholz et al., 2013). Furthermore, sFRPs facilitate the 
diffusion of Wnt ligands extracellularly, thus providing an alternate function to sFRP 
molecules as Wnt transporters (Mii and Taira, 2009). Altogether, considering these diverse 
observations on the sFRPs’ activity, it can be postulated that they could have a distinct 
pattern of expression and, depending on the cellular context, sFRPs can either potentiate or 
regulate several developmental decisions. 
Role of sFRP-Wnt interactions in AD development and progression 
Although their detailed mechanism of action and their role in neurodegenerative diseases are 
poorly understood, sFRP-Wnt interactions could orchestrate a series of sequential events for 
Alzheimer’s progression. Being a member of extracellular Wnt inhibitors, sFRPs function 
similar to other antagonists, such as Dkk-1 (Inestrosa and Toledo, 2008; Caraci et al., 2008) 
and WIF -1 (Hu et al., 2008), to modulate the Wnt β-catenin dependent pathway. Loss or 
impairment in Wnt signals has been recently marked as a molecular tag in AD pathogenesis 
(Inestrosa and Varela-Nallar, 2014). Induction of Dkk-1, and the resultant ß-amyloid toxicity 
observed in cultured neural cells (Killick et al., 2014; Purro et al., 2014), has been found to be 
under the mechanistic regulation of a key enzyme modulator of the Wnt pathway, namely 
GSK3ß. Additionally, GSK3ß has been recently proposed to be the connecting link between 
the two pathological AD markers, namely the tau protein containing neurofibrillary tangles 
(NFT) and the ß-amyloid plaques (Llorens-Martín et al., 2014). Elevated GSK3β activity 
hasa direct link to increased Aβ production and Aβ deposits, tau hyperphosphorylation, and 
synaptic damage in AD patients (Reddy et al., 2000; Benedetti et al., 2013). Although 
evidence on the direct interactions of sFRPs on regulating Wnt activity in the AD brain is 
lacking, their functional role in attenuating ß-catenin signaling has been demonstrated to be 
via GSK3ß (Bovolento et al., 2010). Moreover, sFRPs are reported to be involved in the 
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decline of both cytoplasmic and membrane associated ß-catenin in other cellular contexts that 
include pancreatic islets (Lee et al., 2008), retinal cells (Esteve et al., 2003), and caudal 
neural tubes (Dann et al., 2001). Conversely, an sFRP1 deletion study in mice demonstrated 
reinstated Wnt pathway activation and signaling (Gong et al., 2014), suggesting the potential 
involvement of these proteins in Wnt related functions. Unlike Dkks, sFRPs can interact with 
both ß-catenin dependent and independent Wnt signaling pathways (Marchetti and Pluchino, 
2013; Muley et al., 2010). Therefore, in an sFRP over-expressed system, they antagonize Wnt 
actions either by binding directly to Wnts or competing with FZD receptors, and thus 
preventing Wnt–FZD interactions. As a result of these interactions, the GSK3ß enzyme in the 
destruction complex targets ß-catenin to ubiquitin-mediated degradation cycles. One can 
speculate that this inhibition of Wnt/ß-catenin-mediated signaling could result in the 
accumulation of tau protein and the formation of NFT in the AD brain. This, in turn, disrupts 
nuclear localization of ß-catenin and activation of the TCF/LEF promoter, which initiates 
apoptosis that could lead to neuronal instability and formation of amyloid plaques (Fig.2). 
Subsequent depletion of ß-catenin levels has been correlated to the presence of amyloid 
plaques during the progressive phases of AD (Maguschak and Ressler, 2012). Thus, the 
previously observed inverse relation between ß-catenin signaling and GSK3ß activity in AD 
brains (Avrahami et al., 2013; Hernández et al., 2010) and rat hippocampal neurons (Salcedo- 
Tello et al., 2011) leads us to speculate that there is another possible involvement of sFRPs as 
mediators in deregulating the Wnt signaling pathway. Another study demonstrated that Wnt-
5a was able to reduce synaptic damage and protect against memory loss in AD, and that this 
beneficial effect was blocked by sFRP2 (Zhang et al., 2015). Although further substantiation 
of their functions in neuro-regulatory activities is required, one can expect to recapitulate 
sFRP-mediated events in the AD brain similar to the reported functions of Dkk-1 (Llorens-
Martín et al., 2014), but with wider implications because of the involvement of multiple 
15 
 
cascades of the Wnt pathway in sFRP signal transduction. Hence, it would be worthwhile to 
consider sFRPs in a wider aspect to understand their mechanistic role as Wnt inhibitors in 
neuroderegulation. 
sFRPs as potential therapeutic targets for AD treatment 
In comparison to Dkk-1 or other Wnt inhibitors, sFRP-based targeted strategies are in the 
early stages of investigation (Fontenot et al., 2013). Expression profiling studies of sFRPs 
have demonstrated their up-regulation in most neurological diseases (Esteve et al., 2011; 
Stuckenholz et al., 2013). However, no study has explicitly identified the neuro-regulatory 
activities of sFRPs in Alzheimer’s progression. Given the complexity of the action of sFRPs 
on Wnt signaling, it is possible this family of Wnt mediators could have a diverse effect on 
AD progression. Depending on their expression levels and cellular context within the CNS, 
sFRPs could simultaneously interact with Wnt and FZD to elicit varied responses. A 
systematic delineation of expression the sFRP family of proteins in AD progression would 
help to determine sFRPs as stage-specific biomarkers and as therapeutic targets in the 
degenerative neuropathology of AD. As sFRPs have a broad effect across the multiple 
pathways of Wnt signaling, such an approach would help in a wider capture of the 
neurodegeneration caused by a dysfunctional Wnt machinery. A deeper understanding of the 
molecular mechanism of action of sFRPs in Wnt regulation, in the context of Alzheimer’s 
neurodegeneration, could provide a framework for designing novel sFRP-targeted therapies 
in AD. 
The effect of sFRP on Wnt signaling in the CNS is most likely to be inhibitory because of its 
binding to both the ligand and the receptor. The binding to FZD by the CRD domain of sFRP 
may not be sufficient to elicit the complex assembly of the Axin conglomerate, required for 
the downstream activation of ß -catenin. The binding at the FZD receptor could be further 
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exacerbated by Aß also binding to FZD close to the binding site of Wnt.  Targeting the sFRPs 
to relieve its suppression on the Wnt pathway could be achieved by designing small molecule 
inhibitors for different sFRPs, similar to the diarylsulfone sulphonamide inhibitor for sFRP1 
(Bodine et al., 2009), obtained by high throughput screening.  
 
Conclusion 
The need to identify dysfunctional regulatory networks in AD is compelling in order to 
design novel and effective drug targets. As the present modalities in AD therapies are mostly 
aimed at administering symptomatic treatments, there is a direct need for causative targeting 
of the disease, which will not only help in AD regression but also in early pre-symptomatic 
identification of the disease. With the advent of early biomarkers for AD related to the Wnt 
pathway, there could be hope for more accurate and early diagnosis and promising therapy 
for this debilitating disease. Therefore, we propose that sFRPs could have a profound role in 
AD and could be exploited as novel biomarkers for early detection. Targeting sFRPs might 
be a more promising strategy than other inhibitors such as GSK3ß or DKK because of the 
ability of sFRPs to modulate the multiple Wnt-driven signaling events. Furthermore, as a 
corollary, targeting their expression could bring about amelioration of neurodegenerative 
changes associated with AD.  
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FIGURE LEGENDS 
Fig 1. The β-catenin dependent and independent pathways of Wnt signaling 
Extracellular ligand Wnt acts through the  β-catenin dependent or via the β-catenin 
independent pathways, through the Frizzled (FZD) receptor and via the activation of 
intracellular disheveled (DVL) or heteromeric G-proteins. In the β-catenin dependent 
pathway, β-catenin is activated and transported to the nucleus for downstream activation 
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of Wnt target genes via the T-cell factor/Lymphoid enhancer factor (TCF/LEF) 
promotor. In the β-catenin independent pathway, binding of Wnt to FZD activates either 
the Ca2+ pathway or the planar cell polarity pathway, which are involved in cell survival 
and cytoskeletal formation through actin regulation. (CAMK-Calcium/calmodulin-
dependent protein kinase, protein kinase C - PKC, Jun-N-terminal kinase- JNK,  
Activating transcription factor 2- ATF-2, cAMP-response element-binding protein- 
CREB, N-Methyl-D-aspartate receptors- NMDAR, post synaptic density-95- PSD-95). 
 
Fig 2. A model for sFRP-mediated inhibition of the Wnt signaling pathways in 
Alzheimer’s disease  
In the Alzheimer’s brain, over-expressed sFRP could bind to Wnt and Frizzled (FZD) to 
destabilize the axin complex and release GSK3ß from the complex, which in turn 
phosphorylates ß-catenin and Tau protein, increases Aß  production, and stalls 
TCF/LEF-initiated transduction of pro-proliferative genes. This could result in the 
accumulation of Tau and ß-amyloid proteins, and the loss of synaptic integrity and 
neuronal damage. Dysregulation of the Wnt/Ca2+ pathway could cause disruption in 
the  N-Methyl-D-aspartate receptors and accumulation of extracellular glutamate.  
 
 
 
